ArticleBMC infectious diseases2026
The pharmacokinetics (PK) / pharmacodynamics (PD) of pretomanid, delamanid and bedaquiline in the BALB/c mouse model of central nervous system tuberculosis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCentral nervous system tuberculosis (CNS-TB) is one of the most destructive diseases with high morbidity and mortality worldwide. The present study aimed to assess the effect of three anti-tuberculosis drugs, pretomanid (PA-824), delamanid (DLM) and bedaquiline (BDQ), in CNS-TB treatment, as single agents in the treatment of CNS-TB, using a BALB/c mouse model, and analyze their concentration levels in various organs, including the brain, plasma, lung and spleen.
methodsTissue distribution of 3 drugs in healthy mice was determined by high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). The in vivo activities of PA-824, DLM, BDQ were assessed in CNS-TB mice model.
resultsThe high Kp values of DLM and PA-824 in the brain of mice suggest that they may be well distributed in brain tissue. Compared with untreated mice, after 8 weeks the bacterial load of all treatment groups decreased by 1.0 to 4.7 log10 CFU/lung, and 1.1 to 3.2 log10 CFU/brain, respectively. Among them, PA-824 showed superior efficacy in the brain, owing to its favorable distribution in brain. DLM at a dose of 5 mg/kg showed a certain degree of anti-mycobacterial activity in the brain, although its effect in the lung and spleen was less pronounced. Although BDQ concentration in the mouse brain was not as low as that in patients’ cerebrospinal fluid (CSF), its therapeutic activity in CNS-TB warrants further investigation.
conclusionsOur findings suggest that PA-824 holds promise as a potential therapeutic option for the treatment of CNS-TB, which can be attributed to its excellent drug distribution in the brain and sustained retention above the MIC throughout the dosing interval. The role of DLM and BDQ in the treatment of CNS-TB still requires more evidence. A more comprehensive understanding of these drugs in CNS-TB could facilitate the development of effective treatment strategies for this devastating disease. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.